1-mesityl-3,3-dimethyl-butan-2-one | 61394-82-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-mesityl-3,3-dimethyl-butan-2-one
• 英文别名: 1-Mesityl-3,3-dimethyl-butan-2-on；3,3-Dimethyl-1-mesityl-2-butanon；3,3-Dimethyl-1-(2,4,6-trimethylphenyl)butan-2-one
• CAS: 61394-82-9
• 化学式: C₁₅H₂₂O
• 分子量: 218.339
• InChiKey: NJMHMZORAIRUEZ-UHFFFAOYSA-N

物化性质

• 沸点：
  307.7±11.0 °C(Predicted)
• 密度：
  0.931±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-mesityl-3,3-dimethyl-butane-1,2-diol 在 硫酸 作用下， 生成 1-mesityl-3,3-dimethyl-butan-2-one
  参考文献：
  名称：

  Energy transition and its implications for environmentally sustainable development in Africa

  摘要：

  Energy transition is the process whereby there is an increase in the volume and proportion of commercial energy, to the extent that it replaces traditional fuels as the main source of energy and having enormous implications for the physical and biotic environment. This energy-environment process has rarely been the focus of research investigation in Africa. Using cross-national data drawn from the African continent, this paper examines and accounts for inter-country variations in the nature and extent of the energy transition process. The empirical analysis reveals that, for the continent as a whole, the extent to which commercial energy replaces traditional fuels is quite low. It varies between 33% and 39%. However, inter-country variations were found to be as high as 90% in countries such as Algeria, Egypt, Libya, Mauritania, Morocco and South Africa; and less than 15% for such countries as Benin, Burkina Faso, The Central African Republic, Ethiopia, Lesotho and Uganda. The key factors explaining inter-county variations in the energy transition process are the level of urbanization and the extent of forest and woodland resources. Other factors of secondary importance include economic growth, incidence of poverty, affordability of electrical appliances, energy trade status of the country in question and the price of commercial fuel. Finally, the paper shows that the identification of these key energy transition-inducing variables is a necessary prerequisite to an effective energy and environmentally sustainable development policy formulation in Africa.

  DOI：

  10.1080/13504500009470041

文献信息

• Durch sterische effekte stabilisierte ß-ketocarbonsäuren
  作者：Herbert Meier、Horst Wengenroth、Wolfgang Lauer、Volker Krause

  DOI：10.1016/s0040-4039(01)93755-4

  日期：1989.1

  Increasing steric hindrance in β-keto carboxylic acids leads to an increasing kinetic stability towards decarboxylation, till systems are reached which are completely stable at room temperature. Simultaneously the tautomeric equilibrium is changed in favour of the (Z)-enol, and finally in favour of the (E)-configurated enol.

  β-酮基羧酸的空间位阻增加，导致脱羧的动力学稳定性增加，直至达到在室温下完全稳定的体系。同时，改变互变异构平衡以有利于（Z）-烯醇，最后有利于（E）-构型的烯醇。
• Substituted hydroxamic acids and uses thereof
  申请人：Blackburn Christopher

  公开号：US20110046157A1

  公开（公告）日：2011-02-24

  This invention provides compounds of formula (I): wherein R 1 , R 2 , G, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

  本发明提供了式(I)的化合物： 其中R1、R2、G、n、p和q的值如说明书所述，可用作HDAC6的抑制剂。该发明还提供了包括该发明中的化合物的制药组合物以及使用该组合物治疗增生性、炎症性、感染性、神经系统或心血管疾病或紊乱的方法。
• SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20140329836A1

  公开（公告）日：2014-11-06

  This invention provides compounds of formula (I): wherein R 1 , R 2 , G, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

  本发明提供了式(I)的化合物：其中R1、R2、G、n、p和q的值如规范所述，可用作HDAC6的抑制剂。本发明还提供了包含本发明化合物的制药组合物和使用该组合物治疗增生性、炎症性、感染性、神经系统或心血管疾病或障碍的方法。
• Dark reactions of halobenzenes with pinacolone enolate ion. Evidence for a thermally induced aromatic SRN1 reaction
  作者：Richard G. Scamehorn、Joseph F. Bunnett

  DOI：10.1021/jo00428a039

  日期：1977.4
• MEIER, HERBERT;WENGENROTH, HORST;LAUER, WOLFGANG;KRAUSE, VOLKER, TETRAHEDRON LETT., 30,(1989) N9, C. 5253-5256
  作者：MEIER, HERBERT、WENGENROTH, HORST、LAUER, WOLFGANG、KRAUSE, VOLKER

  DOI：——

  日期：——